26
|
Toma M, Josan K, Moss R, Bashir J, Cowan S, Kaan A, Ignaszewski A, Cheung A. 248 Right Ventricular Dysfunction Should Not Preclude Left Ventricular Assist Device Explantation in Patients Exhibiting Left Ventricular Recovery. J Heart Lung Transplant 2012. [DOI: 10.1016/j.healun.2012.01.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
27
|
Wilson-McManus J, Hollander Z, Cohen Freue G, Balshaw R, Borchers C, Davies R, Delgado D, Haddad H, Ignaszewski A, Isaac D, Kim D, Mui A, Rajda M, West L, White M, Zieroth S, Keown P, McMaster R, Ng R, McManus B. 82 Blood-Based Biomarker Panels for Diagnosis of Acute Heart Allograft Rejection. J Heart Lung Transplant 2012. [DOI: 10.1016/j.healun.2012.01.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
28
|
Hollander Z, Chen V, Ng R, Balshaw R, Wilson-McManus J, Ignaszewski A, McMaster R, Keown P, McManus B. 250 The Likelihood of Acute Cardiac Rejection Can Be Predicted at Transplantation. J Heart Lung Transplant 2012. [DOI: 10.1016/j.healun.2012.01.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
29
|
Hollander Z, Lazárová M, Ignaszewski A, Chen V, Ng R, Wilson-McManus J, Balshaw R, McMaster R, Keown P, McManus B. 193 Biomarkers of Recovered Heart Function. J Heart Lung Transplant 2012. [DOI: 10.1016/j.healun.2012.01.192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
30
|
Catlin B, Ignaszewski A. N038 At the centre of the strategy: Inaugurating the role of the provincial heart failure clinical nurse specialist in British Columbia. Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.08.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
31
|
Davis M, Higgins J, Kaan A, Ignaszewski A, Cheung A. 298 Outcomes of patients with acute right ventricular failure in the era of mechanical circulatory support. Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
32
|
Cheung A, Soon J, Kaan A, Ignaszewski A, Toma M. 424 Minimally invasive left ventricular assist device implantation improves clinical outcomes. Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
33
|
Josan K, Cheung A, Kaan A, Ignaszewski A, Toma M. 455 Long-term follow up of left ventricular size and function in patients successfully bridged to recovery after left ventricular assist device support. Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.08.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
34
|
Arnold M, Liu P, Howlett J, Kaan A, LeBlanc M, Ignaszewski A, Miroslaw R, Marchiori G. 297 Regional differences in patients referred to outpatient clinics of the Canadian Heart Failure Network (CHFN). Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022] Open
|
35
|
Mangat B, Talyor C, Wong G, Chan S, McLeod K, Isserow S, Ignaszewski A, Ramanathan K. 136 Ethnic disparities in cardiac rehabilitation attendance post-st elevation myocardial infarction (STEMI). Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
36
|
Cowan S, Toma M, Kaan A, Ignaszewski A, Cheung A. 544 Long-term survival in patients receiving an implantable microaxial ventricular assist device for cardiogenic shock. Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
37
|
Weber C, Beaulieu M, Djurdjev O, Er L, Taylor P, Ignaszewski A, Burnett S, Levin A. Towards rational approaches of health care utilization in complex patients: an exploratory randomized trial comparing a novel combined clinic to multiple specialty clinics in patients with renal disease-cardiovascular disease-diabetes. Nephrol Dial Transplant 2011; 27 Suppl 3:iii104-10. [DOI: 10.1093/ndt/gfr292] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Hollander Z, Lin D, Ng R, Wilson-McManus J, Ignaszewski A, Balshaw R, McMaster R, Keown P, McManus B. 177: Normalization of Heart Failure Genomic Markers after Transplantation. J Heart Lung Transplant 2010. [DOI: 10.1016/j.healun.2009.11.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
39
|
Lin D, Cohen Freue G, Hollander Z, Sasaki M, Opushneva N, Imai C, Ignaszewski A, Mui A, Wilson-McManus J, Balshaw R. 149: Combinatorial Biomarkers of Cardiac Allograft Vasculopathy. J Heart Lung Transplant 2010. [DOI: 10.1016/j.healun.2009.11.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
40
|
Chua D, Ignaszewski A. Authors' reply. West J Med 2009. [DOI: 10.1136/bmj.b2006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
41
|
Hollander Z, Freue GC, Lin D, Ignaszewski A, Imai C, Kaan A, Wilson-McManus J, Balshaw R, Ng R, McMaster R, Keown P, McManus B. 474: Combinatorial Diagnostic Biomarkers of Acute Cardiac Allograft Rejection. J Heart Lung Transplant 2009. [DOI: 10.1016/j.healun.2008.11.481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
42
|
Cohen Freue G, Lin D, Imai C, Ignaszewski A, Mancini J, Hollander Z, Bergman A, Sasaki M, Wilson-McManus J, Balshaw R, Ng R, Borchers C, Keown P, McManus B, McMaster R. 341: Proteomic Biomarkers of Chronic Heart Allograft Rejection. J Heart Lung Transplant 2009. [DOI: 10.1016/j.healun.2008.11.348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
43
|
Burns S, McQueen K, Velzen MNV, Kam C, Graham A, Chan S, Bondy G, Frohlich J, Ignaszewski A. Comprehensive care for the prevention and reduction of diabetes: a self-management focused program. Can J Diabetes 2009. [DOI: 10.1016/s1499-2671(09)33046-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Burns S, van Velzen MN, McQueen K, Kam C, Chan S, Graham A, Ignaszewski A, Bondy G, Frohlich G. Targeting diabetes prevention in an interactive, innovative and patient focused multidisciplinary metabolic syndrome program. Can J Diabetes 2009. [DOI: 10.1016/s1499-2671(09)33320-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Abstract
BACKGROUND Nesiritide (Natrecor, Janssen-Ortho Inc, Canada), or recombinant human B-type natriurtic peptide (BNP), is a molecule identical in structure to endogenous BNP-32. This peptide is secreted from cardiac myocytes in response to volume and pressure overload. While high levels of circulating BNP are measured by commercially available assays during acute decompensated heart failure (ADHF), the detection of alternate, potentially more active, but undermeasured forms of BNP needs to be considered. AIM The present review summarizes the molecular and physiological effects of nesiritide in the setting of hospitalized patients with ADHF. In particular, an overview of the molecular structure and circulating isoforms of BNP is given, followed by a discussion of the vasodilatory, renal, antagonistic neurohormonal, pulmonary, anti-inflammatory and cardiac remodelling effects of recombinant human BNP. SUMMARY Nesiritide has beneficial effects in the treatment of ADHF that go beyond the traditional goals of reducing pulmonary capillary wedge pressure, preload and afterload, and relieving symptoms of dyspnea. Therefore, the unique pharmacological profile of this medication provides an additional treatment option for Canadian patients with ADHF.
Collapse
|
46
|
Cohen Freue G, Imai C, Ignaszewski A, Mancini G, Hollander Z, Wilson-McManus J, Balshaw R, Ng R, McMaster R, Keown P, McManus B. 372: Genomic Biomarkers of Chronic Heart Allograft Rejection. J Heart Lung Transplant 2008. [DOI: 10.1016/j.healun.2007.11.383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
47
|
Ross H, Burton J, Pflugfelder P, Cantarovich M, Ignaszewski A, Howlett J, White M, Haddad H, Dorent R, Sips C, Vaillancourt M. 474: Assessing safety and efficacy of Neoral®/everolimus maintenance therapy in cardiac transplant recipients: 12 month data. J Heart Lung Transplant 2007. [DOI: 10.1016/j.healun.2006.11.497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
48
|
Al Riyami A, Chandavimol M, Imai C, Straatman L, Kaan A, Ignaszewski A. 361. J Heart Lung Transplant 2006. [DOI: 10.1016/j.healun.2005.11.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
49
|
Samman A, Imai C, Straatman L, Frolich J, Humphries K, Ignaszewski A. Safety and Efficacy of Rosuvastatin Therapy for the Prevention of Hyperlipidemia in Adult Cardiac Transplant Recipients. J Heart Lung Transplant 2005; 24:1008-13. [PMID: 16102434 DOI: 10.1016/j.healun.2004.07.016] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2004] [Revised: 07/06/2004] [Accepted: 07/14/2004] [Indexed: 10/25/2022] Open
Abstract
BACKGROUND Hyperlipidemia after orthotopic heart transplantation (OHT) is associated with immunosuppression. Many OHT patients have increased lipid levels above published guidelines despite treatment with high doses of statins. Treatment with rosuvastatin (ROS) in OHT patients has not yet been evaluated. Therefore, we assessed its efficacy and safety in an OHT population. METHODS Twenty-one OHT recipients, median age 66 years, whose lipid levels were sub-optimal on the highest tolerated doses of statins, received ROS in addition to standard immunosuppression. Total cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), liver transaminases (AST) and creatinine kinase (CK) were measured before and during treatment with ROS. RESULTS After 6 weeks on an average ROS dose of 10 mg/day, a TC:HDL-C ratio of <4 was reached in 76% of patients, and 70% of patients reached an LDL-C level of <2.5 mmol/liter (100 mg/dl). TC decreased to <5.2 mmol/liter (200 mg/dl) in 80% of patients and TG decreased to <2 mmol/liter (175 mg/dl) in 61% of patients. Except for the HDL-C increase, all changes were statistically significant. The decrease in the median TC:HDL-C ratio between baseline and 6 weeks was also statistically significant (p = 0.001). There were no significant changes in CK or AST levels, and no clinical evidence of myositis. One patient developed myalgia and 2 were withdrawn from the study because of mild elevation of CK (<3-fold upper limit of normal [ULN]). CONCLUSIONS In the setting of tertiary referral centers, ROS appears to be safe and effective in lowering LDL-C in OHT recipients in whom treatment with other statins failed to achieve target LDL-C. No evidence of liver or muscle dysfunction was noted. Long-term studies are needed to ascertain the effect of ROS therapy on incidence of coronary artery disease (CAD) in this population.
Collapse
|
50
|
Levy M, Imai C, Kaan A, Straatman L, Ignaszewski A. Successful aggressive withdrawal of prednisone for de novo heart transplant patients in the era of modern immunosuppression. J Heart Lung Transplant 2005. [DOI: 10.1016/j.healun.2004.12.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|